logo
Plus   Neg
Share
Email

Lilly : CHMP Issues Positive Opinion To Expand Trulicity Label

Eli Lilly and Co. (LLY) said that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP issued a positive opinion recommending an update to the Trulicity or dulaglutide label and indication statement.

The committee agreed the label should include results from the REWIND cardiovascular outcomes trial, which achieved a significant 12 percent risk reduction in major adverse cardiovascular events or MACE.

The CHMP has recommended updating the Trulicity indication to reflect both glycemic control and the impact on cardiovascular events as fundamental considerations in a treatment for people with type 2 diabetes.

In addition, the updated label will reflect the consistent MACE risk reduction with Trulicity across major demographic and disease subgroups.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
eBay Inc. (EBAY) Wednesday reported a fourth-quarter profit that trumped Wall Street analysts' estimates, as did revenues. However, shares of the company slipped over 5% after the company issued a weak outlook for the first quarter. eBay's fourth-quarter profit dropped to $558 million or $0.69 per... Apple Inc. (AAPL) Wednesday reported a first-quarter profit that trumped Wall Street estimates, as the iPhone maker reported its "highest quarterly revenue ever" driven by strong demand for its iPhone 11 and 11 Pro models during the holiday season. The tech giant also issued a strong revenue outlook... New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry.
Follow RTT
>